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Abstract
Background: We examine the potential prognostic and predictive roles of EGFR variant III mutation, EGFR gene
copy number (GCN), human papillomavirus (HPV) infection, c-MET and p16
INK4A protein expression in recurrent or
metastatic squamous cell carcinoma of the head and neck (R/M SCCHN).
Methods: We analyzed the archival tumor specimens of 53 patients who were treated in 4 phase II trials for R/M
SCCHN. Two trials involved the EGFR inhibitor erlotinib, and 2 trials involved non-EGFR targeted agents. EGFRvIII
mutation was determined by quantitative RT-PCR, HPV DNA by Linear Array Genotyping, p16 and c-MET protein
expression by immunohistochemistry, and EGFR GCN by FISH.
Results: EGFRvIII mutation, detected in 22 patients (42%), was associated with better disease control, but no
difference was seen between erlotinib-treated versus non-erlotinib treated patients. EGFRvIII was not associated
with TTP or OS. The presence of HPV DNA (38%), p16 immunostaining (32%), c-MET high expression (58%) and
EGFR amplification (27%), were not associated with response, TTP or OS.
Conclusion: EGFRvIII mutation, present in about 40% of SCCHN, appears to be an unexpected prognostic
biomarker associated with better disease control in R/M SCCHN regardless of treatment with erlotinib. Larger
prospective studies are required to validate its significance.
Background
The epidermal growth factor receptor (EGFR) is over-
expressed in up to 90% of squamous cell carcinoma of
the head and neck (SCCHN) and has been postulated to
be a key molecular target in this malignancy [1]. EGFR
signal transduction leads to cell proliferation, invasion,
angiogenesis and metastasis [2]. EGFR overexpression
and aberrant EGFR gene copy number (EGFR GCN)
have been associated with poorer prognosis and disease-
specific survival in SCCHN [1,3,4]. Therapies targeted
against EGFR have demonstrated modest activity either
alone or in combination with chemotherapy in both
locally advanced [5] and recurrent and/or metastatic
SCCHN [6-10]. No validated biomarkers exist to predict
the response to EGFR inhibitors in SCCHN.
The most common EGFR truncation mutation, EGFR
variant III (EGFRvIII), harbors an in-frame deletion of
exons 2 to 7 (801 bp), resulting in a truncated extracel-
lular EGF-binding domain that is constitutively activated
and ineffectively ubiquinated [11,12]. EGFRvIII is found
in many human cancers and is present in ~40% of glio-
blastomas and 5% of lung squamous cell carcinomas,
where it confers tumorigenicity and dose-dependent
resistance to gefitinib in pre-clinical models [13,14]. The
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43% in one study of 33 SCCHN tumors [15]. EGFRvIII-
transfected SCCHN cells had decreased apoptosis in
response to cisplatin and decreased growth inhibition
following treatment with the EGFR monoclonal antibody
cetuximab compared with controls [15]. EGFRvIII is an
interesting therapeutic target because unlike wild-type
EGFR, EGFRvIII is not found in normal tissue. EGFRvIII
is proposed to account for limitations in response to
current EGFR inhibitors, however in patients with
SCCHN tumors harboring EGFRvIII response to EGFR
tyrosine kinase inhibition (TKI) is unknown.
HPV infection is a risk factor for the development of
SCCHN. HPV DNA is found in 20-30% of SCCHN and
up to 40-66% of SCCHN of the oropharynx [16,17].
HPV positive oropharyngeal tumors are clinically and
molecularly distinct from HPV negative tumors [18,19]
and associated with a more favorable prognosis [20].
HPV positive status prospectively predicts survival and
response to induction chemotherapy and chemoradia-
tion in stage III or IV oropharynx cancers [21,22] and
better response to radiotherapy alone [23]. The combi-
nation of low HPV titers and high EGFR expression was
associated with worse overall survival in oropharynx
cancer [22]. Inactivation of pRb by HPV E7 protein
results in overexpression of p16 protein, thus p16
immunostaining has served as a surrogate marker for
HPV-associated SCCHN. Patients with tumors lacking
both p16 expression and HPV (p16-/HPV-) had the
worst disease-specific survival compared to tumors with
p16+/HPV+, p16-/HPV+ or p16+/HPV- types [24].
Despite the importance of HPV in the pathogenesis and
prognosis of SCCHN in response to chemotherapy and
radiation, the role of HPV DNA and response to EGFR
inhibitors in SCCHN is unclear.
c-MET, a proto-oncogene tyrosine kinase receptor, is
overexpressed in SCCHN, and its ligand, hepatocyte
growth factor (HGF), stimulates cell proliferation, moti-
lity and invasion [25]. c-MET overexpression has been
associated with disease progression in oral squamous
cell carcinoma (OSCC) [26]. Elevated serum HGF is
associated with resistance to chemoradiation and
reduced survival [27]. c-MET amplification and muta-
tions of MET confer an invasive phenotype associated
with metastases in SCCHN [28]. Ligand-independent
constitutive activation of c-MET via its heterodimeriza-
tion with EGFR has been identified as a contributing
mechanism of acquired resistance to cetuximab in
SCCHN [29]. The role of c-MET in response to EGFR
TKI in the clinical setting in SCCHN is unknown.
In this study, we examine the prevalence of EGFRvIII,
HPV, p16, c-MET and EGFR GCN in patients with R/M
SCCHN and explore the potential prognostic and pre-
dictive roles of these biomarkers in patients treated with
o rw i t h o u tE G F RT K I .W eh y p o t h e s i z e dt h a tE G F R v I I I
and c-MET would be associated with poorer prognosis
or response to EGFR TKI, while HPV and p16 expres-
sion would predict improved clinical outcomes and
response to treatment.
Methods
Patients
We obtained approval from the University Health Net-
work Research Ethics Board to evaluate the archival for-
malin-fixed paraffin embedded (FFPE) tumor specimens
of patients with R/M SCCHN who were treated in four
phase II trials for R/M SCCHN at Princess Margaret
Hospital conducted from 2000-2005. Two of the four
trials involved the EGFR TKI erlotinib (phase II trial of
erlotinib [8], phase II trial of erlotinib and cisplatin [7])
and the remaining two trials used other non-EGFR tar-
geted agents (phase II trial of the kinesin spindle protein
inhibitor ispinesib [30], phase II trial of the multi-kinase
antiangiogenic inhibitor sorafenib [31]). The medical
records and case report forms were reviewed to obtain
patient demographics, primary tumor site, treatment
details and clinical outcome (response rate, time to pro-
gression and overall survival).
Specimen Characteristics
Archival FFPE tumor specimens were available in 35 of
48 patients (73%) treated with erlotinib and 18 of 37
(49%) patients treated with non-EGFR targeted agents.
H&E stained sections were examined by a histopatholo-
gist (B.P-O.) to confirm the presence of >80% tumor in
the specimens evaluated.
Assay Methods/Molecular Assays
EGFRvIII Mutation Detection
RNA Isolation RNA was isolated in tumor area on the
FFPE slides guided by H&E-stained serial sections. The
tissues were deparaffinized by xylene and ethanol. Total
RNA from paraffin-embedded tissues was extracted
using RecoveryAll™ Total Nucleic Acid isolation Kit
(Ambion Diagnostics, Streetsville, Ontario, Canada).
Real-time RT-PCR Reverse transcription was done
using TaqMan Reverse transcription reagent kit (Roche,
Branchburg, New Jersey) according to the manufac-
turer’s protocol. Reverse transcription reaction was done
in a total volume of 25 mL including RNA template,
1.25 mL random hexamer, reverse transcription buffer,
5.0 mL dNTP, 5.5 mL MgCl, RNase inhibitor, and
M-MLV reverse transcriptase.
Real-time PCR was performed in duplicate in 25 mL
reaction volumes using Platinum SYBR Green qPCR
SuperMix-UDG (Invitrogen, Carlsbad, California) and a
7900HT instrument (Applied Biosystems, Foster City,
California). The amplification conditions were: 50°C for
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60°C for 1 min.
Data Analysis of real-time PCR A mixture of at least
eight normal FFPE tissue samples was used as a wild-
type, normal control. The EGFRvlll cell line (u373fla-
gEGFRvlll) was used as a positive control.
The relative expression of EGFR exon 4 to EGFR exon
9 was determined using the delta delta Ct (ΔΔCt)
method. All samples were run in duplicate, and the
mean Ct number was used for data analysis. The differ-
ence in Ct values (Δthreshold cycle, ΔCt = Exon 9 Ct -
Exon 4 Ct) was calculated for each RNA sample. The
ΔCt from the normal tissue mixture was then subtracted
from the ΔCt of the test sample to generate a ΔΔCt.
A negative result occurs when the fold change (exon 9:
exon 4 calculated as 2
- ΔΔCt)i sl e s st h a nav a l u eo f5 .
This value was arbitrarily chosen to ensure that no false
positives were called. A positive result occurs when the
fold change is the same as or greater than that of the
positive control (7). When the fold change of tested
samples falls between that of the normal control and
the positive control (i.e. between 5 and 7) the results are
considered inconclusive.
HPV DNA Detection
The Roche Linear Array HPV Genotyping kit (Roche
Molecular Diagnostics, Pleasanton, California) was used
to detect 37 low- and high-risk HPV types from FFPE
tissues. In brief, FFPE sections were deparaffinized and
DNA was extracted using a column based method
(QIAamp, Qiagen, Valencia, California). HPV detection
was performed using PCR amplification followed by
hybridization of the amplified products to oligonucleo-
tide probes and subsequent colorimetric determination.
All experiments included an HPV positive control and
an HPV negative control.
HPV DNA by in situ hybridization (ISH) using the
INFORM HPV III Family 16 probe (Ventana Medical
Systems Inc., Tucson, Arizona) which detects genotypes
16, 18, 31, 33, 39, 35, 45, 51, 52, 56, 58 and 66, was per-
formed according to the manufacturer’s guidelines using
the Ventana Benchmark automated slide staining sys-
tem. All experiments included an HPV positive control
and an HPV negative control. Slides were scored as
positive if a punctate or diffuse pattern of signal were
observed in the tumor nuclei.
P16 and c-MET Detection
Immunohistochemistry (IHC) for p16 and c-MET using
the Ventana Benchmark XT auto-immunostainer
(Tucson, Arizona) was performed on FFPE sections cut
at 4mm thick. Standardized staining protocols were pro-
vided by Ventana for the CINtec p16 Histology kit
(MTM Laboratories Inc, Westborough Massachusetts)
and c-MET antibody (SP44, rabbit monoclonal, Ventana
Medical Systems Inc., Tucson Arizona). Controls were
included in each assay, comprising of positive tissue
controls and negative controls. All p16 and c-MET IHC
slides were reviewed independently by two observers
(B.P.O. and N.G.C.) without knowledge of EGFRvIII,
HPV status or clinical outcome. p16 staining in SCCHN
is generally observed to be dichotomous and scored as
absent (weak or no staining) or present (strong and dif-
fuse staining) [32]. c-MET IHC slides were assigned a
semi-quantitative score based on the product of an
intensity score (0 = no staining or equal to background,
1 = weak, or 2 = strong) and percent of area stained
(0 = 0%, 1 = 1-30%, 2 = 31-60%, 3 = >60%). Sections
with an inter-observer variation were reassessed by a
double-headed light microscope to achieve consensus.
EGFR Gene Copy Number
Archival tumor specimens were analyzed for EGFR
GCN using fluorescent in situ hybridization (FISH) as
previously described [33,34]. One hundred non-overlap-
ping interphase nuclei were scored for EGFR and CEP7
copy number and classified into six categories (Univer-
sity of Colorado Scoring system) by a reviewer blinded
to clinical outcome (O.L.) [35].
Statistical Methods
Descriptive statistics were used to summarize the study
cohort and to estimate the parameters of interest.
Ninety-five percent confidence intervals were obtained
for estimates of the presence of EGFRvIII, HPV, p16,
c-MET and EGFR GCN. Exploratory analyses were per-
formed to characterize the relationships between EGFR-
vIII, HPV, p16, c-MET and EGFR GCN with baseline
patient characteristics and outcomes. Only patients with
conclusive EGFRvIII results were included in the corre-
lation analyses. The Kaplan-Meier method was used to
estimate the overall survival and time to progression. All
biomarkers were examined in univariate analysis of
overall survival and time to progression using Cox pro-
portional hazards model. Only those which were signifi-
cant at 0.10 (two-sided) level in the univariate analysis
were entered in the multivariate analysis and markers
that remained significant at 0.05 (two-sided) level in the
multivariate analysis were considered significant prog-
nostic factors. Statistical analyses were performed using
t h eS A S9 . 1s o f t w a r ep a c k a g e( S A SI n s t i t u t e ,C a r y ,
North Carolina).
Results
Patients
The clinical characteristics of the 53 patients in our
study are described in Table 1. For the entire cohort,
the overall response rate (CR+PR) to study treatment
was 4/53 (7.5%), median time to progression (TTP) was
1.8 months (95% CI 1.6-2.7) and median overall survival
(OS) was 5.9 months (95% CI 4.5-8.7). Patients in the
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(95% CI 4.7-9.8) compared to patients in the non-
erlotinib group with median OS of 4.2 months (95% CI
2.9-7.0) (p = 0.011). The erlotinib group had a higher
TTP than the non-erlotinib group 2.7 months (95% CI
1.6-3.5) vs 1.5 months (95% CI 1.3-1.8) (p = 0.0009).
Expression of EGFRvIII mutation by real-time PCR
As the previously reported immunohistochemistry-suitable
antibody [15] against EGFRvIII is no longer available,
EGFRvIII expression is analysed using the RT-PCR
method. The presence of EGFRvIII mutation was detected
in 22 patients (42%) (Table 2), negative in 19 patients and
inconclusive in 12 patients (Table 3). The median EGFR-
vIII fold change was 6.8 (0.56 to 576.36) for all patients,
15.0 (4.1 to 576.36) for patients in the EGFRvIII positive
group, 1.8 (0.6 to 4.3) for patients in the EGFRvIII negative
group, and 6.5 (6.2 to 6.8) for patients in the inconclusive
group.
Patients with tumors harboring the EGFRvIII mutation
had similar clinical characteristics to patients without
the EGFRvIII mutation (Table 4).
EGFRvIII is associated with disease control In univari-
ate analysis, the presence of EGFRvIII was associated
with better disease control (Table 5). Median EGFRvIII
fold changes were higher for patients with disease con-
trol than patients with progressive disease (11.11 vs.
3.16, p = 0.04). No significant difference was observed
between erlotinib-treated (p = 0.21) versus non-erlotinib
(p = 0.10) treated patients due to the small sample size
(Table 5). The presence of EGFRvIII mutation was not
associated with TTP (HR 0.94 (95% CI 0.33-2.71), p =
0.91) or OS (HR 0.91 (95% CI 0.32-2.60), p = 0.85)
(Figure 1).
HPV DNA
HPV DNA testing by PCR was positive in 20 patients
(38%), negative in 31 patients and inconclusive in 2
patients (Tables 2 and 3). The most prevalent HPV sub-
type found in our analysis was the high-risk HPV-16
(18/20 cases). The majority of HPV-16 positive tumors
were from the oropharynx (12/18). HPV positive tumor
status was not significantly associated with disease con-
trol (Table 6), TTP (HR 1.19 (95% CI 0.46-3.11), p =
0.722) or OS (HR 0.88 (95% CI 0.34-2.29), p = 0.788).
P16
P16 immunoreactivity was detected in 17 patients (32%),
absent in 33 patients and inconclusive in 3 patients
(Tables 2 and 3). The inter-observer variability rate was
6% and discrepant cases were resolved by consensus
review. P16 expression was not associated with disease
control (Table 6), TTP (HR 0.50 (95% CI 0.19-1.32), p =
0.16) or OS (HR 0.61 (95%CI 0.24-1.55), p = 0.30).
The discordance between p16 IHC and HPV DNA by
PCR was 25% (Table 7). To investigate this further, we
performed HPV DNA by ISH. The discordance between
p16 IHC and HPV DNA by ISH was lower at 16%
(Table 7) and all 7 discordant cases were p16-positive/
HPV-ISH-negative. Of these 7 discordant cases, 2 cases
were HPV-16 positive by PCR, 4 cases were HPV nega-
tive by PCR and 1 case was inconclusive by HPV PCR.
C-MET
Forty-nine patients had sufficient tumor samples for
evaluation of c-MET. Eighteen patients (63%) had low
c-MET scores of 0, 1 or 2 and 31 patients had high
c-MET (>2) (Tables 2 and 3). Less than 10% inter-
observer variability was observed and discrepant cases
were resolved by consensus review. High c-MET was
not associated with disease control (Table 6), TTP (HR
1.47 (95%CI 0.56-3.85), p = 0.43) or OS (HR 1.72 (95%
CI 0.65-4.56), p = 0.27).
Table 1 Clinical characteristics of the entire study cohort
(n = 53)
Clinical Characteristic Number
Median Age (Range) 56 (15-78)
Gender Female:Male 12:41
ECOG Performance Status 0:1:2 15:34:4
Locoregional Recurrence Yes:No 45:8
Distant Metastases Yes:No 19:34
Primary Tumor Site Oropharynx 20
Larynx 14
Oral cavity 10
Hypopharynx 2
Neck mass unknown 4
Paranasal sinus 3
Histologic Grade Well differentiated 5
Moderately differentiated 33
Poorly differentiated 14
Infiltrating basaloid 1
Prior Therapy Chemotherapy 21
Radiation Therapy 51
Surgery 41
Race Asian 8
Black 42
Caucasian 9
Other 1
Smoker Current 33
Former 3
Never 15
Unknown 2
Erlotinib Yes: No 35:18
Best Response Partial response 4
Stable disease 20
Progressive disease 24
Inevaluable 5
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Forty-five patients had sufficient tumor samples for eva-
luation of EGFR GCN by FISH. High EGFR GCN
(amplification and high polysomy) was detected in 13
patients and low EGFR GCN (disomy, low polysomy)
was detected in 33 patients (Tables 2 and 3). High
EGFR GCN was not predictive for TTP (HR 0.99, p =
0.822) or OS (HR 1.10, p = 0.644). High EGFR GCN
was not associated with the presence of EGFRvIII (p =
0.14 Fisher’s exact test).
Discussion
To the best of our knowledge, this is the first study to
evaluate the role of EGFRvIII in a cohort of patients
with R/M SCCHN treated with or without EGFR TKI.
This study confirms that EGFRvIII mutation is common
Table 2 EGFRvIII mutation positive detected by RT-PCR (n = 22)
Case Treatment Primary Site Specimen Site EGFRvIII by
RT-PCR
EGFRvIII Fold
Changes
HPV DNA by
Linear Array
P16
IHC
MET score
by IHC
EGFR FISH
1 Erlotinib hypopharynx Untreated
primary
+ 11.33 - - High Low
polysomy
2 Erlotinib oral cavity Untreated
primary
+ 7.01 - - High Disomy
3 Erlotinib larynx Untreated
primary
+ 61.77 - - Low Low
polysomy
4 Erlotinib larynx Local
recurrence
+ 26.64 - - Low High
polysomy
5 Erlotinib neck mass
unknown primary
Untreated
lymph node
+ 60.04 33 + + High Low trisomy
6 Erlotinib oral cavity Untreated
lymph node
+ 218.49 - - High Amplification
7 Erlotinib oropharynx Unknown
primary
+ 15.66 16 + + High Low trisomy
8 Erlotinib oral cavity Local
recurrence
+ 8.94 - - High Low
polysomy
9 Erlotinib +
Cisplatin
neck mass
unknown primary
Untreated
lymph node
+ 127.84 16+ NE NE Low trisomy
10 Erlotinib +
Cisplatin
larynx Node
recurrence
+ 576.36 16+ + High Disomy
11 Erlotinib +
Cisplatin
larynx Untreated
primary
+ 8.26 - - Low Failed
12 Erlotinib +
Cisplatin
larynx Untreated
primary
+ 17.38 - - High Low
polysomy
13 Erlotinib +
Cisplatin
oropharynx Untreated
primary
+ 14.28 16+ + High Disomy
14 Erlotinib +
Cisplatin
oral cavity Untreated
primary
+ 69.68 - NE NE Low
polysomy
15 Erlotinib +
Cisplatin
oral cavity Untreated
primary
+ 11.11 53+, 58+, 6+, 52+ - High Low
polysomy
16 Sorafenib oropharynx Untreated
primary
+ 7.71 16 + + Low Low
polysomy
17 Sorafenib oropharynx Untreated
primary
+ 7.93 16 + + Low Low trisomy
18 Ispinesib neck mass
unknown primary
Untreated
lymph node
+ 4.12 16+, 53+, 51 + + High High
polysomy
19 Ispinesib oropharynx Untreated
primary
+ 15.61 16+, 53+, 33+, 51
+, 58 +
- High High
polysomy
20 Ispinesib larynx Untreated
primary
+ 218.26 - - High Disomy
21 Ispinesib oropharynx Local
recurrence
+ 29.25 16+, 53+, 51+ + Low Disomy
22 Ispinesib hypopharynx Local
recurrence
+ 9.31 16+, 53+, 58+, 52
+
- High Low
polysomy
Abbreviations: +, positive; -, negative; NE, not evaluable.
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Case Treatment Primary Site Specimen
Site
EGFRvIII by
RT-PCR
EGFRvIII Fold
Changes
HPV DNA by
Linear Array
P16
IHC
MET score
by IHC
EGFR FISH
23 Erlotinib larynx Local
recurrence
- 1.76 - - High Low polysomy
24 Erlotinib larynx Untreated
primary
- 0.95 - - NE NE
25 Erlotinib oropharynx Untreated
primary
Incon. NE 16 + - Low Failed
26 Erlotinib larynx Untreated Incon. NE - - NE NE
27 Erlotinib oropharynx Local
recurrence
- 2.56 16 + - High Failed
28 Erlotinib neck mass
unknown primary
Local
recurrence
- 1.81 - - High Low polysomy
29 Erlotinib paranasal sinus Untreated
primary
- 0.56 - - High High polysomy
30 Erlotinib oropharynx Untreated
primary
- 3.16 16 + + High Low trisomy
31 Erlotinib larynx Untreated
primary
- 3.17 - - High Low polysomy
32 Erlotinib oropharynx Local
recurrence
NE NE - + Low Low polysomy
33 Erlotinib larynx Untreated
primary
- 3.16 - - High High trisomy
34 Erlotinib +
Cisplatin
oropharynx Untreated
primary
Incon. NE Incon. + Low NE
35 Erlotinib +
Cisplatin
larynx Untreated
primary
- 4.29 - - Low Low polysomy
36 Erlotinib +
Cisplatin
oral cavity Untreated
primary
- 0.9 - - Low High polysomy
37 Erlotinib +
Cisplatin
paransal sinus Local
recurrence
Incon. NE 16+, 53+ Incon. Low Low polysomy
38 Erlotinib +
Cisplatin
larynx Local
recurrence
Incon. NE 16+, 53+, 33+, 51
+
+ High Disomy
39 Erlotinib +
Cisplatin
paranasal sinus Local
recurrence
- 2.59 6+ - High NE
40 Erlotinib +
Cisplatin
oral cavity Untreated
primary
- 2.01 - - High Disomy
41 Erlotinib +
Cisplatin
oropharynx Untreated
primary
Incon. NE - + High Low trisomy
42 Erlotinib +
Cisplatin
oral cavity Untreated
primary
Incon. NE - - High High polysomy
43 Sorafenib oral cavity Untreated
primary
Incon. 6.8 - - Low Low polysomy
44 Sorafenib oropharynx Untreated
primary
- 0.99 - + High Amplification/
High trisomy
45 Sorafenib oral cavity Local
recurrence
Incon. NE Incon. - Low Low polysomy
46 Sorafenib oropharynx Untreated
primary
Incon. 6.22 16 + + Low Low trisomy
47 Sorafenib larynx Local
recurrence
- 2.28 - + High High polysomy
48 Sorafenib oropharynx Untreated
primary
- 0.64 - - High Low polysomy
49 Sorafenib oropharynx Local
recurrence
- 1.4 - - High High polysomy
50 Sorafenib oropharynx Local
recurrence
- 1.3 - - High High polysomy
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identified EGFRvIII mutation in 42% of 53 R/M SCCHN
tumors. This is in keeping with the first description of
EGFRvIII expression by IHC and RT-PCR in 42% of 33
SCCHN tumors sampled [15]. In vitro studies suggest
that EGFRvIII mutated SCCHN cell lines are resistant
to the anti-EGFR monoclonal antibody cetuximab [15].
In this study, EGFRvIII was not associated with an infer-
ior response to erlotinib therapy. Importantly, we
observed a significant association between the presence
of EGFRvIII (mean fold change and copy number by
RT-PCR) with greater disease control, regardless of
treatment with erlotinib, suggesting that perhaps EGFR-
vIII may have a prognostic role.
The prognostic or predictive significance of the EGFR-
vIII mutation in response to systemic therapy in patients
with SCCHN has not been previously described. The
potential prognostic role of EGFRvIII appears to be
independent of any clinicopathologic characteristics.
This is consistent with another study where EGFRvIII
detected by IHC in 234 of 681 locally advanced SCCHN
tumors (34%) was associated with increased tumor size
but not stage or other clinical factors [36]. In our study,
EGFRvIII was not associated with overall survival or
TTP. To our knowledge, EGFRvIII has not been linked
to survival in SCCHN. EGFRvIII has been described
more extensively in glioblastoma where it results in
enhanced proliferation and reduced apoptosis effects
that are mediated through increased levels of activated
Ras [37] and activation of the PI3K pathway [38]. How-
ever, the role of EGFRvIII as a prognostic or predictive
marker of response to EGFR inhibitors in glioblastoma
remains controversial. EGFRvIII and PTEN co-expres-
sion was associated with response to EGFR TKI in 26
patients out of a cohort of 49 patients with recurrent
glioma and a validation set of 33 patients [39]. EGFRvIII
has been reported as a prognostic marker for poorer
survival in some studies [40,41], but not in others
[42,43]. Conflicting results have been attributed to small
sample sizes with incomplete clinical data and varying
methods to detect EGFRvIII.
The presence of activating mutations conferring a bet-
ter prognosis has been reported with EGFR mutations
in non-small cell lung cancer (NSCLC) [44] and with
PIK3CA mutations in breast cancer [45]. Somatic acti-
vating mutations (exon 19 deletion and 21 point muta-
tion) in the EGFR tyrosine kinase domain confer
sensitivity to EGFR inhibitors in NSCLC. Patients with
Table 3 EGFRvIII mutation negative detected by RT-PCR (n = 19) and inconclusive cases (n = 12) (Continued)
51 Sorafenib oropharynx Local
recurrence
- 1.76 - + Low Monosomy/
Disomy
52 Ispinesib oropharynx Untreated
lymph node
Incon. NE - - High Low polysomy
53 Ispinesib oropharynx Node
recurrence
- 4.05 16 + - Low Amplification
Abbreviations: +, positive; -, negative; Incon., inconclusive; NE, not evaluable.
Table 4 Presence of the EGFRvIII mutation is not significantly associated with any clinical characteristics
Clinical Characteristic EGFRvIII absent (n = 19) EGFRvIII present (n = 22) p-value
Male - no., (%) 16 (84%) 18 (82%) 0.839 (Fisher’s)
Age - mean, (+/-SD) 53.5 (+/- 11.6) 55.1 (+/- 14.1) 0.685 (t-test)
Oropharynx - no., (%) 8 (42%) 6 (27%) 0.318 (Chi-square)
Larynx - no., (%) 6 (32%) 6 (27%) 0.763 (Chi-square)
Oral Cavity - no., (%) 2 (11%) 5 (23%) 0.271 (Fisher’s)
Distant metastasis - no., (%) 4 (21%) 12 (55%) 0.053 (Fisher’s)
Locoregional recurrence - no., (%) 18 (95%) 16 (73%) 0.099 (Fisher’s)
Well-moderately differentiated - no., (%) 15 (79%) 14 (64%) 0.325 (Fisher’s)
Poorly differentiated - no., (%) 4 (21%) 8 (36%)
Prior chemotherapy - no., (%) 9 (47%) 8 (36%) 0.476 (Chi-square)
Prior radiotherapy - no., (%) 17 (89%) 22 (100%) 0.209 (Fisher’s)
Prior surgery - no., (%) 17 (89%) 17 (77%) 0.419 (Fisher’s)
Caucasian - no., (%) 15 (79%) 18 (82%) 0.562 (Fisher’s)
Erlotinib treatment - no., (%) 12 (63%) 15 (68%) 0.735 (Chi-square)
No erlotinib treatment - no., (%) 7 (38%) 7 (32%)
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response to chemotherapy alone [46] or placebo [47].
This suggests that EGFR mutations in NSCLC are a
good prognostic factor independent of EGFR TKI, hence
i tm a yb em o r ed i f f i c u l tt od e m o n s t r a t et h ev a l u eo f
EGFR mutations as predictors of benefit to EGFR TKI
[44]. The prognostic value of EGFRvIII in SCCHN
needs to be verified, and its role as a predictive marker
of response to EGFR inhibitor should remain a relevant
therapeutic question.
In this study, the prevalence of HPV, p16 and c-MET
expression (38%, 32% and 63% respectively) was in
keeping with the literature. We did not observe HPV,
p16 and c-MET expression to be predictive of disease
control, TTP or OS. This may be due to limitations of a
small sample size. Consistent with prior reports [21],
HPV-16 was the most common HPV subtype in our
study. c-MET is a poor prognostic marker in OSCC
[48], however the small proportion (11%) of OSCC in
our study precludes any meaningful association.
Limitations of this study include its small sample
size, potential bias towards patients with available
tumor specimens (larger tumor size), potentially vari-
able fixation and quality of the archival tissues and
Table 5 EGFRvIII mutation is associated with disease control
EGFRvIII Best Response
Progressive Disease Disease Control (Partial Response or Stable Disease)
EGFRvIII absent by ΔΔCt 12 (67%) 6 (33%) P = 0.0099
EGFRvIII present by ΔΔCt 5 (25%) 15 (75%) (Chi-square)
EGFRvIII mean fold change 10.62 63.76 P = 0.04
EGFRvIII median fold change 3.16 11.11 (Wilcoxon)
Erlotinib treated patients
EGFRvIII absent by ΔΔCt 6 (55%) 5 (45%) P = 0.21
EGFRvIII present by ΔΔCt 3 (33%) 10 (77%) (Fisher’s)
Non-erlotinib treated patients
EGFRvIII absent by ΔΔCt 6 (86%) 1 (14%) P = 0.21
EGFRvIII present by ΔΔCt 2 (29%) 5 (71%) (Fisher’s)
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Figure 1 Overall survival by EGFRvIII mutation status (HR = 0.91, 95% CI: 0.32-2.60, p = 0.85).
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Page 8 of 11potential variation in marker status of primary tumor
compared with recurrent or metastatic tumors (to our
knowledge, this is theoretical and has not been
described). Due to the absence of an untreated control
group in this study (’control’ patients received sorafe-
nib or ispinesib), our results cannot conclusively con-
firm the prognostic versus predictive value of a
biomarker. Although our methods did not use an anti-
body for EGFRvIII detection, we acknowledge that the
use of RT-PCR in FFPE samples has demonstrated
superior accuracy relative to IHC tests [49] and may
allow greater applicability to settings where frozen tis-
sue is unavailable.
Conclusion
Predictors of response to EGFR inhibitors in SCCHN
remain elusive. Biomarkers are desperately needed to
guide patient selection in SCCHN. EGFRvIII remains an
interesting tumor-specific target worthy of further
exploration as a prognostic or predictive marker of
response to EGFR inhibitor therapy in SCCHN. Larger
prospective randomized studies are required to distin-
guish the prognostic and predictive significance of
EGFRvIII, HPV, p16, c-MET and EGFR GCN in
SCCHN treated with EGFR inhibitors.
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